Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicentre, Phase 3 Scintigraphy Study Assessing 123I-mIBG Uptake in Subjects Being Evaluated for Phaeochromocytoma or Neuroblastoma

NCT00126412 is registered in ClinicalTrials.gov with GE Healthcare as lead sponsor.

NCT NCT00126412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00126412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicentre, Phase 3 Scintigraphy Study Assessing 123I-mIBG Uptake in Subjects Being Evaluated for Phaeochromocytoma or Neuroblastoma
Lead sponsor
GE Healthcare
Phase
Phase 3
Overall status
Completed
Start date
August 2, 2005
Completion date
September 27, 2006
Enrollment
251 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma, pheochromocytoma